Disclosures for "Barriers and Solutions for Initiating Monoclonal Antibody Therapy in Alzheimer’s Disease"
-
Dr. Gelblum has received personal compensation in the range of $10,000-$49,999 for serving as a Consultant for Eisai. Dr. Gelblum has received personal compensation in the range of $5,000-$9,999 for serving on a Speakers Bureau for Eisai.
-
Dr. Yoest has received personal compensation for serving as an employee of MedThink SciCom.
-
Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Roche. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Iqvia. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Acumen. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Eisai. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Novartis. Dr. Weisman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for eisai. Dr. Weisman has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Lantheus. Dr. Weisman has received personal compensation in the range of $50,000-$99,999 for serving on a Speakers Bureau for Eisai. Dr. Weisman has received personal compensation in the range of $10,000-$49,999 for serving on a Speakers Bureau for Lilly. The institution of Dr. Weisman has received research support from Eisai. The institution of Dr. Weisman has received research support from Biogen. The institution of Dr. Weisman has received research support from Roche. The institution of Dr. Weisman has received research support from Vivoryon. The institution of Dr. Weisman has received research support from Lilly. The institution of Dr. Weisman has received research support from Acumen. The institution of Dr. Weisman has received research support from Cerevel. The institution of Dr. Weisman has received research support from Sage. The institution of Dr. Weisman has received research support from Annovis. The institution of Dr. Weisman has received research support from Serono. The institution of Dr. Weisman has received research support from Acadia. The institution of Dr. Weisman has received research support from Alnylam. The institution of Dr. Weisman has received research support from Ventus. The institution of Dr. Weisman has received research support from Cognition. Dr. Weisman has received intellectual property interests from a discovery or technology relating to health care. Dr. Weisman has received intellectual property interests from a discovery or technology relating to health care. Dr. Weisman has received personal compensation in the range of $500-$4,999 for serving as a Peripheral and Central Nervous System Drugs Advisory Committee with FDA.